May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Co–Existent Open–Angle Glaucoma and Cataract: Treatment by Cataract Surgery and the iStenttm Trabecular Bypass Micro Stent
Author Affiliations & Notes
  • D. Spiegel
    Ophthalmology, University Eye Hosp Regensburg, Regensburg, Germany
  • W. Wetzel
    Augenaerztliche Gemeinschaftspraxis, Weinheim, Germany
  • J. Sturmer
    Ophthalmology, Augenklinik Kantonsspital, Winterthur, Switzerland
  • H. Hoh
    Klinikum Neubrandenburg, Neubrandenburg, Germany
  • T. Neuhann
    Rotkreuz Krankenhaus, Munchen, Germany
  • J. Garcia–Sanchez
    Clinico San Carlos, Madrid, Spain
  • R.A. Hill
    Ophthalmology, University California Irvine, Irvine, CA
  • B. Niksch
    Glaukos Corporation, Laguna Hills, CA
  • Footnotes
    Commercial Relationships  D. Spiegel, None; W. Wetzel, None; J. Sturmer, None; H. Hoh, None; T. Neuhann, None; J. Garcia–Sanchez, None; R.A. Hill, Glaukos Corporation I, C, P, R; B. Niksch, Glaukos Corporation E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 74. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Spiegel, W. Wetzel, J. Sturmer, H. Hoh, T. Neuhann, J. Garcia–Sanchez, R.A. Hill, B. Niksch; Co–Existent Open–Angle Glaucoma and Cataract: Treatment by Cataract Surgery and the iStenttm Trabecular Bypass Micro Stent . Invest. Ophthalmol. Vis. Sci. 2005;46(13):74.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Title: Co–existent open–angle glaucoma and cataract: Treatment by cataract surgery and the iStentTM Trabecular Bypass Micro Stent Purpose:To evaluate the safety and efficacy of the Glaukos iStentTM Trabecular Bypass Micro Stent implanted in conjunction with cataract surgery. Methods: Prospective study of 51 patients with "uncontrolled open angle glaucoma (including pseudoexfoliation)" and cataract. Subjects underwent clear cornea phacoemulsification cataract extraction with ab–interno gonioscopically guided implantation of the iStentTM. Results: In this interim analysis of 44 of 51 subjects, with a mean follow–up of 4.71 months (range: 1 to 12 months). At baseline, mean (± SD) IOP was 21.18 ± 3.25 mmHg (range 18–29), and patients were taking 1.48 ± 0.63 ocular hypotensive medications. A "last visit" analysis revealed a mean decrease in IOP of 4.98 ± 4.01 mmHg (p<0.0001), and a decrease in the number of ocular hypotensive medications to 0.52 ± 0.88 (p<0.0001). For the 8 patients with 12 months or more follow–up, the mean IOP was 16.0mmHg ± 3.16mmHg. These subjects exhibited a mean decrease in IOP of 6.88 ± 5.36 mmHg. There were no complications traditionally associated with filtering surgery, and minimal adverse events reported. Conclusions: In this interim analysis in a population of subjects with glaucoma and cataracts, ab–interno, iStentTM implantation in conjunction with cataract surgery represents a new surgical approach to provide clinically significant decreases in IOP and drug burden.

Keywords: intraocular pressure • trabecular meshwork • cataract 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.